Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP)
Post# of 721
(Total Views: 266)
Posted On: 03/01/2018 6:42:44 PM
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Enters Seven-Year Licensing Agreement with Cannfections Group, Inc.
- Cannabis-infused chocolates and candies, such as gummies, will be manufactured using LXRP’s next-generation, patented technology to be sold in Canada and internationally, where permitted
- LXRP’s goal is to partner with manufacturers who provide best-in-class products to existing large consumer groups
- Licensing DehydraTECH™ is key to LXRP’s generation of revenue; LXRP aims to license its IP in all countries where its technology is patented or patent pending
Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) continues to generate revenue from licensing its proprietary and patented technology DehydraTECH™, which is already patented in the U.S. and Australia. The company also has multiple patents pending in more than 40 countries globally.
Lexaria’s entry into a seven-year definitive licensing agreement with Cannfections Group, Inc. in Canada is a major step toward bringing its improved delivery methodologies to market (http://nnw.fm/1g0MN). DehydraTECH promotes healthier ingestion methods and lower overall dosing. Cannfections is expected to leverage the platform by manufacturing and marketing cannabis-infused chocolates and candies for the legalized adult market.
Cannfections contract manufactures chocolate retail products for several international and domestic chocolate brands. The company believes that the agreement should lead not only to new product entries for Canadian cannabis edibles, but to exports to international markets, where permitted. In addition, the agreement permits LXRP to offer other licensee partners the option of using Cannfection’s manufacturing expertise to produce cannabis-infused chocolates and gummies powered by DehydraTECH technology.
DehydraTECH has been shown to increase intestinal absorption rates and provide for more rapid delivery of active ingredients to the bloodstream. It also offers taste-masking benefits for orally-administered molecules, including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs and nicotine.
“By licensing our technology to Cannfections, Lexaria can now offer its commercial clients the expertise of one of Canada’s oldest and most established chocolatiers utilizing next-generation DehydraTECH technology,” Chris Bunka, CEO of Lexaria, stated in a news release. “This is a long term strategic relationship meant to offer technology, value and expertise to Licensed Producers wanting to offer the highest quality chocolate edibles available in Canada once permitted under Health Canada regulations.”
For more information, visit the company’s website at www.LexariaBioscience.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Cannabis-infused chocolates and candies, such as gummies, will be manufactured using LXRP’s next-generation, patented technology to be sold in Canada and internationally, where permitted
- LXRP’s goal is to partner with manufacturers who provide best-in-class products to existing large consumer groups
- Licensing DehydraTECH™ is key to LXRP’s generation of revenue; LXRP aims to license its IP in all countries where its technology is patented or patent pending
Lexaria Bioscience Corp. (OTCQX: LXRP) (CSE: LXX) continues to generate revenue from licensing its proprietary and patented technology DehydraTECH™, which is already patented in the U.S. and Australia. The company also has multiple patents pending in more than 40 countries globally.
Lexaria’s entry into a seven-year definitive licensing agreement with Cannfections Group, Inc. in Canada is a major step toward bringing its improved delivery methodologies to market (http://nnw.fm/1g0MN). DehydraTECH promotes healthier ingestion methods and lower overall dosing. Cannfections is expected to leverage the platform by manufacturing and marketing cannabis-infused chocolates and candies for the legalized adult market.
Cannfections contract manufactures chocolate retail products for several international and domestic chocolate brands. The company believes that the agreement should lead not only to new product entries for Canadian cannabis edibles, but to exports to international markets, where permitted. In addition, the agreement permits LXRP to offer other licensee partners the option of using Cannfection’s manufacturing expertise to produce cannabis-infused chocolates and gummies powered by DehydraTECH technology.
DehydraTECH has been shown to increase intestinal absorption rates and provide for more rapid delivery of active ingredients to the bloodstream. It also offers taste-masking benefits for orally-administered molecules, including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs and nicotine.
“By licensing our technology to Cannfections, Lexaria can now offer its commercial clients the expertise of one of Canada’s oldest and most established chocolatiers utilizing next-generation DehydraTECH technology,” Chris Bunka, CEO of Lexaria, stated in a news release. “This is a long term strategic relationship meant to offer technology, value and expertise to Licensed Producers wanting to offer the highest quality chocolate edibles available in Canada once permitted under Health Canada regulations.”
For more information, visit the company’s website at www.LexariaBioscience.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Lexaria Bioscience Corp. (LXRPD) Stock Research Links
Scroll down for more posts ▼